MINDLIGHT Trademark

Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for medical purposes; Medical laboratory analysis services relating to the treatment of persons, namely, detecting circular RNA biomarkers for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of persons, namely, namely detecting circular RNA biomarkers for the diagnostic assessment of a major depressive disorder (MDD); Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for the diagnosis of a major depression disorder; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers for medical purposes; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for the diagnosis of psychiatric and neurological disorders; Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for major depressive disorders (MDD); Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples to determine if the patient will respond to selective serotonin reuptake inhibitor (SSRI) treatment; Medical laboratory analysis services relating to the treatment of patients, namely, detecting circular RNA biomarkers in blood samples for predicting patient response to selective serotonin reuptake inhibitor (SSRI) and disease prognosis based on SSRI treatment; and Medical diagnostic testing, monitoring and reporting services, namely diagnostic testing, monitoring and reporting of circular RNA biomarkers in blood samples for predicting patient response to SSRI for treatment of major depressive disorder (MDD) and predicting disease prognosis following treatment